Design and Analysis Issues for Economic Analysis Alongside Clinical Trials
暂无分享,去创建一个
[1] S. Crawford,et al. A comparison of anlaytic methods for non-random missingness of outcome data. , 1995, Journal of clinical epidemiology.
[2] M. Drummond,et al. Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations? , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[3] M J Buxton,et al. Modelling in economic evaluation: an unavoidable fact of life. , 1997, Health economics.
[4] A. Willan. Statistical analysis of cost–effectiveness data from randomized clinical trials , 2006, Expert review of pharmacoeconomics & outcomes research.
[5] Bernie J. O'Brien,et al. In Search of Power and Significance: Issues in the Design and Analysis of Stochastic Cost-Effectiveness Studies in Health Care , 1994, Medical care.
[6] J. Concato,et al. Randomized, controlled trials, observational studies, and the hierarchy of research designs. , 2000, The New England journal of medicine.
[7] D. Rubin,et al. Reducing Bias in Observational Studies Using Subclassification on the Propensity Score , 1984 .
[8] N. Olchanski,et al. Growth and quality of the cost-utility literature, 1976-2001. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[9] Andrew R Willan,et al. 'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data. , 2006, PharmacoEconomics.
[10] B. O'brien,et al. Challenges for Model-Based Economic Evaluations of Postmenopausal Osteoporosis Interventions , 2001, Osteoporosis International.
[11] Michael Drummond,et al. Assessing the appropriateness of combining economic data from multinational clinical trials , 2003, Statistics in medicine.
[12] D. Torgerson,et al. Bootstrapping: estimating confidence intervals for cost-effectiveness ratios. , 1999, QJM : monthly journal of the Association of Physicians.
[13] Anthony O'Hagan,et al. On estimators of medical costs with censored data. , 2004, Journal of health economics.
[14] Simon G Thompson,et al. Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. , 2005, Health economics.
[15] Andrew Briggs,et al. Missing... presumed at random: cost-analysis of incomplete data. , 2003, Health economics.
[16] Ruth Etzioni,et al. Estimating the costs attributable to a disease with application to ovarian cancer. , 1996, Journal of clinical epidemiology.
[17] Andrew R Willan,et al. Regression methods for cost‐effectiveness analysis with censored data , 2005, Statistics in medicine.
[18] E. Topol,et al. Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.
[19] Milton C Weinstein,et al. Comparative effectiveness: asking the right questions, choosing the right method. , 2005, Health affairs.
[20] S. Wilson. Methods for the economic evaluation of health care programmes , 1987 .
[21] G. Wilensky. Developing a center for comparative effectiveness information. , 2006, Health affairs.
[22] John Mullahy,et al. Net Health Benefits: A New Framework for the Analysis of Uncertainty in Cost-Effectiveness Analysis , 1998 .
[23] M. Sculpher,et al. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. , 2005, Health economics.
[24] J. Lellouch,et al. Explanatory and pragmatic attitudes in therapeutical trials. , 1967, Journal of chronic diseases.
[25] W. Stalman,et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease , 2005, Neurology.
[26] E. Feuer,et al. Estimating medical costs from incomplete follow-up data. , 1997, Biometrics.
[27] G. Torrance,et al. Economic evaluation of controlled-release oxycodone vs oxycodone-acetaminophen for osteoarthritis pain of the hip or knee. , 2006, The American journal of managed care.
[28] Peter C Austin,et al. A critical appraisal of propensity‐score matching in the medical literature between 1996 and 2003 , 2008, Statistics in medicine.
[29] M J Al,et al. Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.
[30] Joseph C Gardiner,et al. Longitudinal analysis of censored medical cost data. , 2006, Health economics.
[31] D. Stryer,et al. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. , 2003, JAMA.
[32] S. Thompson,et al. How should cost data in pragmatic randomised trials be analysed? , 2000, BMJ : British Medical Journal.
[33] R. Willke,et al. Estimating country-specific cost-effectiveness from multinational clinical trials. , 1998, Health economics.
[34] D. Revicki,et al. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. , 1999, PharmacoEconomics.
[35] S. Shoor,et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study , 2005, The Lancet.
[36] A A Stinnett,et al. Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[37] T. Wagner,et al. Behavioral interventions and cost-effectiveness analysis. , 2004, Preventive medicine.
[38] B. O'brien,et al. Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials? , 1996, Medical care.
[39] G. Torrance,et al. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers. , 2003, Ostomy/wound management.
[40] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[41] M. Drummond,et al. A rational framework for decision making by the National Institute For Clinical Excellence (NICE) , 2002, The Lancet.
[42] D. Torgerson,et al. Confidence intervals for cost-effectiveness ratios: the use of 'bootstrapping'. , 1997, Journal of health services research & policy.
[43] Mark Sculpher,et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[44] O Johnell,et al. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. , 1996, BMJ.
[45] Martin J Buxton,et al. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. , 2003, Health economics.
[46] S G Thompson,et al. Analysis and interpretation of cost data in randomised controlled trials: review of published studies , 1998, BMJ.
[47] A. Levy,et al. Assessing the impact of censoring of costs and effects on health-care decision-making: an example using the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[48] M. Drummond,et al. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. , 2003, Chest.
[49] E. Wagner,et al. Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs. , 1995, Journal of clinical epidemiology.
[50] S. Sonnad,et al. Diffusion of published cost-utility analyses in the field of health policy and practice , 2005, International Journal of Technology Assessment in Health Care.
[51] M. Drummond,et al. Trials and Tribulations: Emerging Issues in Designing Economic Evaluations Alongside Clinical Trials , 1998, International Journal of Technology Assessment in Health Care.
[52] Elisabeth Fenwick,et al. A guide to cost-effectiveness acceptability curves. , 2005, The British journal of psychiatry : the journal of mental science.
[53] Richard Willke,et al. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[54] B. O'brien,et al. Cost-Effectiveness of Rhythm versus Rate Control in Atrial Fibrillation , 2004, Annals of Internal Medicine.
[55] D Menon,et al. Canadian Coordinating Office for Health Technology Assessment. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[56] A Briggs,et al. Economic evaluation and clinical trials: size matters , 2000, BMJ : British Medical Journal.
[57] C Michael Stein,et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease , 2002, The Lancet.
[58] R. Willke,et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[59] A. Hartz,et al. A comparison of observational studies and randomized, controlled trials. , 2000, The New England journal of medicine.
[60] L. Garrison,et al. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[61] Andrew Briggs,et al. Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. , 2004, Health economics.